Near-infrared probe for early diagnosis of diabetic complications-nephropathy and in vivo visualization fluorescence imaging research

Diabetic nephropathy is one of the common complications of diabetes, which has high risk of renal function. Dipeptidyl peptidase 4 (DPP4) is considered to be one of the good dynamic monitoring indicators for early diabetic nephropathy. Therefore, real-time monitoring of changes in the activity of DPP4 in organisms is helpful to the diagnosis and treatment of diabetes and its complications-diabetic nephropathy. A near-infrared fluorescent probe GP-DCMNH2 is designed to detect the activity of DPP4. GP-DCMNH2 is catalyzed and hydrolyzed by DPP4 into the near-infrared fluorescent dye DCMNH2, to achieve the purpose of detecting DPP4 in organisms. Based on the excellent near-infrared spectroscopy characteristics displayed by the probe GP-DCMNH2 in vitro, in living cells and diabetic mouse models, GP-DCMNH2 has been further applied in the visual fluorescence imaging of diabetic complications-diabetic nephropathy. Compared with the control group and the treatment group, GP-DCMNH2 showed a stronger near-infrared fluorescence signal in the kidney tissue and blood of diabetic nephropathy mice. Because GP-DCMNH2 shows high sensitivity in real-time dynamic monitoring of changes in the activity of DPP4 in organisms, and shows strong practicability in the spectral test of mouse models of diabetes and diabetic nephropathy. In clinical medicine, GP-DCMNH2 is expected to be used in the early diagnosis, prevention and treatment of diabetes and diabetic nephropathy.